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Abstract
Background: Potential role of computerized decision support system on management of atrial fibrillation is not well understood.
Objectives: To systematically review studies that evaluate the effects of computerized decision support systems and decision aids on 
aspects pertaining to atrial fibrillation.
Data Sources: We searched Medline, Scopus and Cochrane database. Last date of search was 2016, January 10.
Selection criteria: Computerized decision support systems that help manage atrial fibrillation and decision aids that provide useful 
knowledge for patients with atrial fibrillation and help them to self-care.
Data collection and analysis: Two reviewers extracted data and summarized findings. Due to heterogeneity, meta-analysis was not 
feasible; mean differences of outcomes and confidence intervals for a difference between two Means were reported.
Results: Seven eligible studies were included in the final review. There was one observational study without controls, three observational 
studies with controls, one Non-Randomized Controlled Trial and two Randomized Controlled Trials. The interventions were three decision 
aids that were used by patients and four computerized decision support systems. Main outcomes of studies were: stroke events and major 
bleeding (one article), Changing doctor-nurse behavior (three articles), Time in therapeutic International Normalized Ratio range (one article), 
decision conflict scale (two articles), patient knowledge and anxiety about stroke and bleeding (two articles).
Conclusions: A computerized decision support system may decrease decision conflict and increase knowledge of patients with atrial 
fibrillation (AF) about risks of AF and AF treatments. Effect of computerized decision support system on outcomes such as changing doctor-
nurse behavior, anxiety about stroke and bleeding and stroke events could not be shown.We need more studies to evaluate the role of 
computerized decision support system in patients with atrial fibrillation.
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Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia and 
its prevalence increases with age[1]. One in five strokes are associated 
with AF and stroke severity is increased compared to patients with 
other causes of stroke. Furthermore, AF is associated with increased 
rates of death, heart failure and hospitalizations[2].
AF is almost a chronic disease and Lifelong treatment is needed. 
To avoid thromboembolic complications, Patients with AF need 
anticoagulation therapy and the most used drug is Vitamin K 
antagonists (like warfarin)[3]. Treatment with anticoagulant warfarin 
has to be monitored by prothrombin Ratio (PR) and the International 
Normalized Ratio ( INR )[4]. Range 2 to 3 (therapeutic range) of 
INR minimize thromboembolic events for patients with AF.
Numerous guidelines exist for the management of AF. CHA2DS2-
VASc [5] and HAS-BLED [6] scores can help to inform stroke risk and 
risk of bleeding [7]. However, physicians’ adherence to these guidelines 
has been low [8]. Computerized Decision Support Systems (CDSS) 
have been postulated as promising tools to improve the quality of 
decisions [9] in terms of physician adherence [10], [11]. Hence, decision 
support systems have been designed to implement guidelines also for 
the management of AF [12].
To investigate the advantages of CDSSs for the management of 
AF, several studies have been conducted which reported a positive 
effect [13] or no effect but according to our knowledge no review has 
been done to integrate these results.
Many reviews have shown effects of CDSS on practitioner 
performance [14]-[16] by providing patient-specific information and 
evidence-based recommendations. We therefore aim to systematically 
review studies that evaluate the effects of CDSS on any aspect that 
we will encounter in the studies. The specific aims of this scoping 
review are: 1) To review what outcome types that evaluate effect 
of CDSS on AF have been studied. 2) To summarize the effect of 
CDSS on management of AF.
Methods 
   For the current review CDSS is defined as any intervention that 
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presents clinical knowledge and patient specific information for 
providers to enhance health and health care [17]. All aspects of AF 
(prevention, detection, diagnosis and treatment) were considered. 
Information sources were: Medline, Scopus and Cochrane database 
and last date searched was 2016, January 10.
Search strategy and study selection
    Our full electronic search strategy for Medline was:
 (clinical decision support systems[MESH] OR decision 
support system*[TITLE/ABSTRACT] OR decision support 
tool*[TITLE/ABSTRACT] OR reminder system*[TITLE/
ABSTRACT] OR reminding system*[TITLE/ABSTRACT] OR 
alert system*[title/abstract] OR alerting system*[title/abstract] OR 
computer assisted decision making[MESH] OR computer assisted 
decision making[TITLE/ABSTRACT] OR diagnosis, computer 
assisted[MESH] OR computer assisted diagnosis[TITLE/
ABSTRACT] OR computer assisted therapy[MESH] OR computer 
assisted therapy[TITLE/ABSTRACT] OR expert systems[MESH] 
OR expert system*[TITLE/ABSTRACT] OR *CDS*[TITLE/
ABSTRACT] OR medical order entry systems[MESH] OR 
order entry system*[TITLE/ABSTRACT] OR computerized 
order entry[TITLE/ABSTRACT] OR computerized prescriber 
order entry[TITLE/ABSTRACT] OR computerized provider 
order entry[TITLE/ABSTRACT] OR computerized physician 
order entry[TITLE/ABSTRACT] OR electronic order 
entry[TITLE/ABSTRACT] OR automated order entry[TITLE/
ABSTRACT] OR CPOE[TITLE/ABSTRACT]OR electronic 
prescribing[MESH] OR electronic prescribing[TITLE/
ABSTRACT] OR electronic prescription[TITLE/ABSTRACT] 
OR computer assisted therapy[MESH] OR computer assisted 
therapy[TITLE/ABSTRACT] OR computer assisted drug 
therapy[TITLE/ABSTRACT]) AND (atrial fibrillation*[TITLE/
ABSTRACT] OR Auricular Fibrillation*[TITLE/ABSTRACT] 
OR Atrial Fibrillation [MESH]).
This search strategy was modified for other databases.
Inclusion criteria were:
1. Studies evaluating effects of a CDSS on all aspects of AF. 
2. CDSS provided clinical knowledge to augment clinician decisions 
or patient specific information to reinforce patient decisions. 
3. Real world clinical studies. 
Exclusion criteria were: 
4. Letters, abstracts, conference proceeding, study protocols, reviews 
and meta-analysis. 
5. Studies that only assessed accuracy and sensitivity. 
   Searching was complemented by reviewing bibliographies listed 
in identified articles. Two reviewers screened the titles and abstracts 
and evaluated the eligibility of studies for detailed evaluation. 
Disagreements were resolved through consensus or consulting a third 
reviewer.
Data collection process
 Two reviewers extracted, separately, data from the selected 
studies. Data items were: participants (sample size, audience and 
characteristics), type of the interventions, primary and secondary 
outcomes, design of studies (cross sectional, case control, cohort, 
before-and-after and Randomized Control Trial (RCT)) and results 
of the studies.
Data collection process
   Selected studies were evaluated using a previously published tool in 
Table 1:  The tool used to rate the quality of the studies
Quality assessment aspects score
Allocation to study groups
Random 2
Quasi-random 1
Selected concurrent control 0
Data analysis and presentation of results
Appropriate & clear 2
Inappropriate or unclear 1
Inappropriate & unclear 0
Presence of baseline differences between the groups
No baseline differences present or appropriate statistical 
adjustment made
2
Baseline differences present & no statistical adjustment made 1
Baseline characteristics not reported 0
Objectivity of the outcomes
Objective outcomes or subjective outcomes with blinded 
assessment
2
Subjective outcomes with no blinding but clear criteria 1
Subjective outcomes with no blinding & poorly defined 0
Completeness of follow-up for the appropriate unit of analysis
90% 2
From 80% to 90% 1
< 80% or not described 0
Each item has a score between 0 to 2.
Figure 1: Flow diagram for selecting of studies.
prevention of cardiovascular disease [18]. It provides a maximum of 10 
points for quality. The following aspects were considered: Allocation 
to study groups, data analysis and presentation of results, presence of 
baseline differences, objective outcomes and percentage of follow-up 
[Table 1].
   Studies were classified according to type of outcomes. Effects of 
CDSS on each outcome were extracted and classified as statistically 
significant positive effects and no effect. Mean differences of 
outcomes and confidence intervals for a difference between two 
means are reported. The included studies were heterogeneous 
and were classified as being one of: Randomized Controlled Trial 
(RCT), Non-Randomized Controlled Trial (before-after studies), 
Observational study with controls (cross-sectional studies and cohort 
studies with controls ), Observational study without controls (cohort 
studies without controls or case series)[19].
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and stroke was proposed. The patients who actually received an 
anticoagulant when the CDSS was not in practice used but after that 
decision support tool recommended not to use the anticoagulant, had 
a high risk of bleeding and for them receiving warfarin was related to 
increased hazard of bleeding (Hazard ratio=1.54, p=0.03).
Changing doctor-nurse behavior
  Two trials reported changing physician behavior [22], [24]. In one cohort 
study with historical control, an automated system for identifying 
newly diagnosed AF was proposed [24]. A computerized clinical alert 
system was developed by decision rules intended to automatically 
notify physicians. In the control period 94 patients were high risk 
and 34 of them (36%) received warfarin but in the notification period 
125 patients were high risk and 34 of them (27%) received warfarin. 
(Odds ratio, 0.66 [95% CI, 0.37–1.17]; p = 0.16). The intervention 
did not change provider behaviors. In [22] was performed a cross 
sectional analysis with a mixed intervention (guidance, education, 
software enhancements and evaluative feedback). CHA2DS2-VASc 
and HAS-BLED scores were calculated and Pop-up reminders were 
used. From April 2011 to April 2013, oral anticoagulant use increase 
from 52.6% to 59.8% (trend difference P<0.001). One trial reported 
changing nurse behavior. The cohort study with historical control 
reported guideline adherence in the treatment of AF as an outcome 
[23]. Computer-Assisted Decision Support System directed medical 
therapy according to the patient’s profile and clinical guidelines. 
Guideline adherence was increased significantly to 96% in the ICT-
supported integrated chronic care program (ICCP) group compared 
with 70% in the control group (p<0.001).
Effects of decision aids on outcomes of studies 
Time in the therapeutic INR range
  One before and after study reported the Percentage of time spent 
within the therapeutic range (TTR) [21]. Patients received the 
recommended dose based of a decision support tool. No significant 
difference in TTR occurred between the before and after intervention 
periods (82.9% vs 81.2%, p=0.65).
Decision conflict
   Decision conflict scale [26] was used for reporting the decision 
Results
Study selection
   Our search strategy yielded 1292 distinct articles from all sources. 
1263 articles were excluded by assessing the title and abstract. Full 
text assessment of the 29 articles was done and seven eligible studies 
were included in the final review [Figure 1].
Study characteristics
   All papers were published after 2007. The following study types 
were present in our final selection: one observational study without 
controls [20], one non-RCT [21], three observational studies with 
controls [22]-[24] and two RCTs [13], [25]. The sample size of AF patients, 
varied from 44 [21] to 6,123 [20] [Table 2]. Two studies were conducted 
in an inpatient setting and five in an outpatient setting. Patients 
were excluded if they were ambulatory patients or on a cardiology 
service [24], receiving warfarin for less than 6 months [21], did not speak 
English [25], poor hearing or eyesight [13], cognitive impairment [13], 
[25], contraindication to ASA or warfarin [13], [25], taking warfarin for 
another indication [13], [25], nursing home residence [13], previous stroke 
or transient ischemic attack [25] , inpatients [23] and no patients were 
excluded from one study [22]. Computerized tools were used in six 
papers and an intervention consisting of a CDSS, education and 
feedback, was used in one paper [22]. Three of the tools were decision 
aids and were used by patients [13], [21], [25]. Five papers were of high 
quality and two papers were of poor quality (on a scale of 10, 5 or less 
than 5 was their score). Details of quality evaluation are presented in 
table 3.
Effects of CDSS on outcomes of studies
  The included studies differed in study design and/or type of 
interventions and/or in their control groups. Main outcomes were: 
stroke events and major bleeding, changing doctor-nurse behavior, 
time in therapeutic INR range, decision conflict scale, patient 
knowledge and anxiety about stroke and bleeding [Table 4]. Below 
we address each outcome separately.
Stroke events and major bleeding
   Acute stroke and major bleeding were assessed in a cohort study 
[20]. A decision support tool that determines patient’s risk of bleeding 
Table 2: Characteristics of the included studies
Authors, year of 
publication
Sample size Setting Type of intervention audience Design of study
Cook, D. A. et al [24], 
2015
Control period No. (n = 226 
patients),
Notification period No. (n = 268 
patients)
inpatient CDSS(clinical alert system that 
notify providers of abnormal test 
results)
Provider (physician) Observational study with 
controls
Robson, J. et al [22], 
2014
4604 patients outpatient Mixed (altering professional beliefs 
using education, CDSS to facilitate 
decision making and motivating 
change using evaluative feedback)
Provider (physician) Observational study with 
controls
Simmons, B. J. et al [21], 
2012
44 patients outpatient Decision aid ( patient self-
management (PSM) program)
patients Non-RCT
Fraenkel, L. et al [13], 
2012
Control group (n = 66 patients),
Intervention group (n = 69 patients )
outpatient Decision aid (a tool for nonvalvular 
atrial fibrillation (NVAF) to notify 
patients of their stroke and bleeding 
risks, assist in clarifying priorities)
patients RCT
Hendriks, J. M. L.et al 
[23], 2010
ICCP group(n=111 patients)
control group(n=102 patients)
outpatient CDSS(stroke risk score was 
calculated and 2006 guidelines for 
AF patients were implemented)
Provider (nurse) Observational study with 
controls
Wess, M. L. et al [20], 
2008
6,123 patients inpatient CDSS( a tool to calculate individual 
stroke and bleeding risk and risk–
benefit analysis for anticoagulation 
is done)
provider Observational study 
without controls
Thomson, R. G [25], 
2007
109 patients (intervention(n=53)
control(n=56))
outpatient decision aid(applied in shared 
decision-making clinic)
patients RCT
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defined question and assessed the quality of included studies. But as 
we will explain below we had only one or two studies that reported 
the same results for outcomes and we had different study designs. we 
could not answer specific review questions so we decided to do the 
scoping review that had broader topics and is possible with many 
different study designs [28].
   One study reported that a computerized clinical alert system did 
not change providers’ behaviors and reported no effect [24] but another 
reported improvement in clinical management AF [22]. The quality 
of the former was higher than the latter and the latter used a mixed 
intervention. It is difficult to estimate which part of the intervention 
pertained to the reported improvement. Furthermore, only one low 
quality study reported the effect of CDSS on guideline adherence[23] 
conflict between treatment choices (antiplatelet drugs or warfarin 
therapy) in two studies [13], [25]. Four subscales of the decision conflict 
scale are: uncertainty, informed, values clarity, and support.
   In a randomized control trial, a decision aid presented advantages 
and disadvantages of warfarin treatment and an assessment of DCS 
(Decision Conflict Scale) was done. It was lower in the computerized 
decision aid group versus the paper guidelines group, mean differences 
(95% CI) were 0.02 (-0.22 to 0.26), -0.18 (-0.34 to -0.01) and -0.15 
(-0.37 to 0.06) at pre-clinic, post-clinic and three month follow-up 
[25]. In a clustered randomized controlled trial, a decision support tool 
was developed as an application that runs on a laptop computer and 
risks of stroke and bleeding for both antiplatelet drug and warfarin 
were shown. Informed subscale (mean difference = −11.9 , 95% CI 
=−21.1 to −2.7) and Values Clarity subscales (mean difference = 
−14.6, 95% CI=−22.6 to −6.6) were lower in the intervention group 
[13].
Anxiety about stroke and bleeding
   Two RCT studies reported anxiety or worry about stroke and 
bleeding as an outcome [13], [25]. The decision aid was designed for 
informing patient’s stroke and bleeding risks and clarifying priorities 
but did not affect participants’ anxiety (mean difference = −0.38, 95% 
CI = (−1.4 to .67), p=0.477)in [13]. Furthermore, in [25] the intervention 
was a computerized decision aid applied in shared decision-making 
and reduction of anxiety by the decision aid did not differ from the 
control group (F (1, 95) =0.001; p=0.98).
Patient knowledge
    Two trials assessed patient knowledge [13], [25]. Participants in 
the intervention group knew medications for reducing stroke risk 
significantly better than the control group ( 61% vs 31%, p=0.001) 
[13]. Knowledge scores were improved after the clinic (participants 
taking warfarin had a higher mean warfarin knowledge score than 
participants on aspirin (difference=1.79 with 95% CI 1.00 to 2.59)) 
but after three months were back to the pre-clinic level and there was 
no significant difference between the decision aid and the guidelines 
groups [25].
Discussion
     In this study we assessed the effect of CDSS on all aspects of 
AF. We systematically reviewed seven studies. Two RCTs that had 
the highest quality reported positive effect on main outcome [13], 
[25]. Two of the observational study with controls reported positive 
effect on all their outcomes [22], [23] but one of them reported no effect 
on its outcome [24]. Mix of positive, absence of, and negative effects 
was considered as one class of the measured effects in [27] and was 
reported in four of selected studies (two RCTs and one non-RCT 
and one observational study without controls).
   We began to do a systematic review study with focus on a well-
Table 3: Details of quality evaluation
[24] [22] [21] [13] [23] [20] [25]
Allocation to study groups 0 0 0 1 0 0 2
Data analysis and presentation 
of results
2 2 2 1 2 2 2
Presence of baseline differences 
between the groups
2 0 2 2 1 2 2
Objectivity of the outcomes 2 2 2 2 2 2 2
Completeness of follow-up for 
the appropriate unit of analysis
0 0 1 2 0 0 2
Sum of scores 6 4 7 8 5 6 10
Table 4: Outcomes and effect sizes for the selected studies
reference outcome Effect size effect on 
outcome
Quality
rating
[24] Prescription of 
warfarin
In the control period 94 patients 
were high risk and 34 of them 
(36%) received warfarin but in the 
notification period 125 patients 
were high risk and 34 of them 
(27%) received warfarin. (Odds 
ratio, 0.66 [95% CI, 0.37–1.17]; 
p = 0.16).
No effect 6
[22] •The proportion 
of AF patients 
with a CHA2DS2-
VASc score ≥1 on 
anticoagulants
•The proportion 
of AF patients 
with a CHA2DS2-
VASc score ≥1 on 
aspirin
• Oral anticoagulant use 
increased from 52.6% to 59.8% 
(trend difference P<0.001)
• Aspirin use declined from 
37.7% to 30.3% (trend difference 
P<0.001).
• Positive 
(statistically 
significant)
• Positive 
(statistically 
significant
4
[21] • Time in the 
therapeutic INR 
range(TTR)
• number of INR 
tests
• No significant difference in TTR 
occurred between the before and 
after intervention periods (82.9% 
vs 81.2%, p=0.65).
• Intervention increased the 
mean number of INR tests per 
patient (2.97 to 4.38, p<0.01).
• No effect
• Positive 
(statistically 
significant)
7
[13] • Decision 
conflict scale
• Knowledge
• Change in 
treatment
• anxiety
• Informed subscale (mean 
difference = −11.9, 95% CI 
=−21.1 to −2.7) and Values 
Clarity subscales (mean 
difference = −14.6, 95% 
CI=−22.6 to −6.6) were lower in 
the intervention group.
• Participants in the intervention 
group knew medications for 
reducing stroke risk significantly 
better than the control group 
(61% vs 31%, p=0.001).
• Positive 
(statistically 
significant)
• Positive 
(statistically 
significant)
• No effect
• No effect
8
[23] Guideline 
adherence
Guideline adherence was 
increased significantly to 96% 
in the ICT-supported integrated 
chronic care program (ICCP) 
group compared with 70% in the 
control group (p<0.001).
Positive 
(statistically 
significant)
5
[20] • major 
gastrointestinal 
bleeding
• acute stroke
The patients who actually 
received an anticoagulant 
but decision support tool 
recommended not to use the 
anticoagulant, had a high risk of 
bleeding and for them receiving 
warfarin was related to increased 
hazard of gastrointestinal 
bleeding (Hazard ratio=1.54, 
p=0.03).
• Positive 
(statistically 
significant)
• No effect
6
[25] • decision 
conflict scale
• anxiety
• knowledge
Decision Conflict Scale was lower 
in the computerized decision aid 
group versus the paper guidelines 
group in the post-clinic; mean 
Difference -0.18 (95% CI -0.34 
to -0.01).
• Positive 
(statistically 
significant)
• No effect
• No effect
10
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thus we have not enough evidence to determine the effect of CDSS 
on improving guideline adherence and changing doctor-nurse 
behavior in the treatment of AF.
   Reporting no effect of the CDSS on changing physician behavior 
was unsurprising. Other studies of decision support systems showed 
that these do not perform as expected [29]. Inappropriate timing 
and need to click to access information[24] and alert fatigue [30] were 
reported as the main reasons. Improving the human-computer 
interface, providing recommendations for patients in addition to 
practitioners [31], prioritizing and filtering recommendations for the 
user [32] can improve the effectiveness of CDSS interventions.
    Due to scarcity of evidence for clinical improvement [33], [34] we had 
only one study that evaluated stroke events and major bleeding [20]. 
The rates of bleeding were higher in patients who received warfarin, 
but the decision support system indicated they should not so a 
decision support system can be a good predictor of bleeding for who 
warfarin might be harmful. Furthermore, only one study reported the 
percentage of time spent within the therapeutic range (TTR) and it 
did not report on a statistically significant improvement. This lack of 
evidence is a main limitation of our study.
   This study had other limitations. The large heterogeneity in the 
studies meant that meta-analysis is not meaningful. We also could 
not perform pooled analysis because the two high quality RCTs that 
reported on anxiety, the decision conflict scale and patient knowledge 
[13], [25] had different comparison groups: one study compared the 
decision aid group to a usual care group [13] ,the other compared the 
decision aid group with an evidence-based paper guidelines group 
[25]. Furthermore, randomization methods and blinding differed 
markedly, resulting in further heterogeneity among studies.
   Two RCT studies [13], [25] reported no significant difference in 
psychological outcomes such as anxiety between groups. This 
coincides with [35] that reported no difference in anxiety scores 
between decision aid and usual care groups. So decision aids did not 
have psychological negative effects.
    Two studies [13], [25] reported the decision aids for patients with 
AF decrease decisional conflict. This result is similar to a review [36] 
that evaluated effects of educational and behavioral interventions on 
reducing decision conflict for oral anticoagulation therapy (OAT) 
in patients with AF. Moreover, these two RCTs showed that the 
decision aids improve knowledge of patients with AF although one 
study reported that knowledge returned to the baseline level after 
three months and there was no significant difference between the 
decision aid and the guidelines groups [25]. The paper guidelines that 
were used in control group may limit findings significant effect of 
decision support systems on patient knowledge.
  Clear and intuitive user interface was reported as a feature for 
evaluation of CDSS [37] but only two of the included studies [24], 
[25] presented the screen of the computerized intervention. If 
characteristics of output such as content, channel, timing and format 
[38] were clearer, we could more accurately interpret the results of 
interventions and evaluate the effect of these characteristics on 
success of the intervention.
  Strengths of the current review include the fact that we searched 
Medline, Scopus and Cochrane databases and conducted this 
review in accordance with the PRISMA statement [39] for reporting 
on review. As far as we know, this is the first review of studies that 
evaluate the effect of CDSS on all aspects of AF.
  Several trial protocols describe trials that investigate the effect 
of CDSS on AF management [12], [40], [41] but their results are 
not published yet. These randomized control trials may provide 
supplemental evidence.
Conclusions
   Although limited by a small number of studies, decision aids 
seems to have significant benefits in decisional conflict reduction 
and improve knowledge of patients with AF. Computerized tools 
that addressed AF patients did not show the psychological negative 
effect and did not affect participants’ feeling of worry about stroke 
and bleeding. The included studies did not show significant effect 
of CDSS on stroke event rates, time in the therapeutic INR range 
and doctor-nurse behavior. We need more studies to evaluate the 
role of computerized decision support system in patients with atrial 
fibrillation.
Authors’ contributions
   RS and EN screened the titles and abstracts and evaluated the 
eligibility of studies and extracted data. Disagreements were resolved 
by MS. RS and MS drafted the paper. AH as a clinical expert and 
SE and AA that are experts in medical informatics, were involved in 
interpretation and revising the final version.
Acknowledgments
  This work was supported by Mashhad University of Medical 
Sciences (MUMS). MUMS had no role in the study design, data 
collection and analysis, reporting the outcomes and decision to 
publish this paper.
Conflicts of interests
    None of the authors has any financial and personal relations with 
relevant people or organizations that could have affected this work.
Disclosures
None.
References
1. January C.T. 2014 AHA/ACC/HRS guideline for the management of patients 
with atrial fibrillation: a report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines and the Heart Rhythm 
Society. J Am Coll Cardiol. 2014;64:1–76.
2. Camm A John, KirchhofPaulus, LipGregory Y H, SchottenUlrich, SavelievaIrene, 
ErnstSabine, Van GelderIsabelle C, Al-AttarNawwar, HindricksGerhard, 
PrendergastBernard, HeidbuchelHein, AlfieriOttavio, AngeliniAnnalisa, 
AtarDan, ColonnaPaolo, De CaterinaRaffaele, De SutterJohan, GoetteAndreas, 
GorenekBulent, HeldalMagnus, HohloserStefan H, KolhPhilippe, Le 
HeuzeyJean-Yves, PonikowskiPiotr, RuttenFrans H. Guidelines for the 
management of atrial fibrillation: the Task Force for the Management of Atrial 
Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 2010;31 
(19):2369–429.
3. Kozlowski Dariusz, BudrejkoSzymon, RaczakGrzegorz, RyszJacek, BanachMaciej. 
Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin 
K antagonists. Curr. Pharm. Des. 2013;19 (21):3816–26.
4. Ansell Jack, HirshJack, HylekElaine, JacobsonAlan, CrowtherMark, 
PalaretiGualtiero. Pharmacology and management of the vitamin K antagonists: 
American College of Chest Physicians Evidence-Based Clinical Practice 
Guidelines (8th Edition). Chest. 2008;133 (6 Suppl):160S–198S.
5. Lip Gregory Y H, NieuwlaatRobby, PistersRon, LaneDeirdre A, CrijnsHarry J G 
M. Refining clinical risk stratification for predicting stroke and thromboembolism 
in atrial fibrillation using a novel risk factor-based approach: the euro heart survey 
on atrial fibrillation. Chest. 2010;137 (2):263–72.
6. Pisters Ron, LaneDeirdre A, NieuwlaatRobby, de VosCees B, CrijnsHarry J G M, 
LipGregory Y H. A novel user-friendly score (HAS-BLED) to assess 1-year risk 
www.jafib.com June-July 2017| Volume 10| Issue 1 
Featured ReviewJournal of Atrial FibrillationJ r l f tri l i rill ti6 Original Research
23. Hendriks J L M, NieuwlaatR, VrijhoefH J M, de WitR, CrijnsH J G M, 
TielemanR G. Improving guideline adherence in the treatment of atrial 
fibrillation by implementing an integrated chronic care program. Neth Heart J. 
2010;18 (10):471–7.
24. Cook David A, EndersFelicity, CaraballoPedro J, NishimuraRick A, LloydFarrell 
J. An automated clinical alert system for newly-diagnosed atrial fibrillation. PLoS 
ONE. 2015;10 (4):–.
25. Thomson Richard G, EcclesMartin P, SteenI Nick, GreenawayJane, 
StobbartLynne, MurtaghMadeleine J, MayCarl R. A patient decision aid to 
support shared decision-making on anti-thrombotic treatment of patients with 
atrial fibrillation: randomised controlled trial. Qual Saf Health Care. 2007;16 
(3):216–23.
26. O’Connor A M. Validation of a decisional conflict scale. Med Decis Making. 
1995;15 (1):25–30.
27. Eslami Saeid, Abu-HannaAmeen, de KeizerNicolette F. Evaluation of outpatient 
computerized physician medication order entry systems: a systematic review. J Am 
Med Inform Assoc. 2007;14 (4):400–6.
28. Arksey H, O’MalleyL. Scoping studies: towards a methodological framework. 
International journal of social research methodology. 2005;8:19–32.
29. Ash Joan S, SittigDean F, CampbellEmily M, GuapponeKenneth P, 
DykstraRichard H. Some unintended consequences of clinical decision support 
systems. AMIA Annu Symp Proc. 2007; ():26–30.
30. Smithburger Pamela L, BuckleyMitchell S, BejianSharon, BurenheideKatie, 
Kane-GillSandra L. A critical evaluation of clinical decision support for the 
detection of drug-drug interactions. Expert Opin Drug Saf. 2011;10 (6):871–82.
31. Roshanov Pavel S, FernandesNatasha, WilczynskiJeff M, HemensBrian J, 
YouJohn J, HandlerSteven M, NieuwlaatRobby, SouzaNathan M, BeyeneJoseph, 
Van SpallHarriette G C, GargAmit X, HaynesR Brian. Features of effective 
computerised clinical decision support systems: meta-regression of 162 
randomised trials. BMJ. 2013;346 ():–.
32. Sittig Dean F, WrightAdam, OsheroffJerome A, MiddletonBlackford, 
TeichJonathan M, AshJoan S, CampbellEmily, BatesDavid W. Grand challenges 
in clinical decision support. J Biomed Inform. 2008;41 (2):387–92.
33. Bright Tiffani J, WongAnthony, DhurjatiRavi, BristowErin, BastianLori, 
CoeytauxRemy R, SamsaGregory, HasselbladVic, WilliamsJohn W, 
MustyMichael D, WingLiz, KendrickAmy S, SandersGillian D, LobachDavid. 
Effect of clinical decision-support systems: a systematic review. Ann. Intern. Med. 
2012;157 (1):29–43.
34. Lobach David, SandersGillian D, BrightTiffani J, WongAnthony, DhurjatiRavi, 
BristowErin, BastianLori, CoeytauxRemy, SamsaGregory, HasselbladVic, 
WilliamsJohn W, WingLiz, MustyMichael, KendrickAmy S. Enabling health care 
decisionmaking through clinical decision support and knowledge management. 
Evid Rep Technol Assess (Full Rep). 2012; (203):1–784.
35. Protheroe Joanne, BowerPeter, Chew-GrahamCarolyn, PetersTim J, FaheyTom. 
Effectiveness of a computerized decision aid in primary care on decision making 
and quality of life in menorrhagia: results of the MENTIP randomized controlled 
trial. Med Decis Making. 2007;27 (5):575–84.
36. Clarkesmith Danielle E, PattisonHelen M, LaneDeirdre A. Educational and 
behavioural interventions for anticoagulant therapy in patients with atrial 
fibrillation. Cochrane Database Syst Rev. 2013; (6):–.
37. Mollon Brent, ChongJaron, HolbrookAnne M, SungMelani, ThabaneLehana, 
FosterGary. Features predicting the success of computerized decision support 
for prescribing: a systematic review of randomized controlled trials. BMC Med 
Inform Decis Mak. 2009;9 ():–.
38. Osheroff J.A. Improving Medication Use and Outcomes with Clinical Decision 
Support:: A Step by Step Guide. HIMSS. 2009;0:0–0.
39. Moher David, LiberatiAlessandro, TetzlaffJennifer, AltmanDouglas G. Preferred 
reporting items for systematic reviews and meta-analyses: the PRISMA statement. 
of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 
2010;138 (5):1093–100.
7. Lane Deirdre A, LipGregory Y H. Use of the CHA(2)DS(2)-VASc and HAS-
BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial 
fibrillation. Circulation. 2012;126 (7):860–5.
8. Ogilvie Isla M, WelnerSharon A, CowellWarren, LipGregory Y H. 
Characterization of the proportion of untreated and antiplatelet therapy treated 
patients with atrial fibrillation. Am. J. Cardiol. 2011;108 (1):151–61.
9. Sintchenko Vitali, CoieraEnrico, IredellJonathan R, GilbertGwendolyn L. 
Comparative impact of guidelines, clinical data, and decision support on 
prescribing decisions: an interactive web experiment with simulated cases. J Am 
Med Inform Assoc. 2003;11 (1):71–7.
10. Moja Lorenzo, KwagKoren H, LytrasTheodore, BertizzoloLorenzo, 
BrandtLinn, PecoraroValentina, RigonGiulio, VaonaAlberto, RuggieroFrancesca, 
MangiaMassimo, IorioAlfonso, KunnamoIlkka, BonovasStefanos. Effectiveness 
of computerized decision support systems linked to electronic health records: a 
systematic review and meta-analysis. Am J Public Health. 2014;104 (12):e12–22.
11. Jamal Aziz, McKenzieKirsten, ClarkMichele. The impact of health information 
technology on the quality of medical and health care: a systematic review. HIM J. 
2009;38 (3):26–37.
12. Arts Derk L, Abu-HannaAmeen, BüllerHarry R, PetersRon J G, EslamiSaeid, 
van WeertHenk C P M. Improving stroke prevention in patients with atrial 
fibrillation. Trials. 2013;14 ():–.
13. Fraenkel Liana, StreetRichard L, TowleVirginia, O’LearyJohn R, IannoneLynne, 
Van NessPeter H, FriedTerri R. A pilot randomized controlled trial of a decision 
support tool to improve the quality of communication and decision-making in 
individuals with atrial fibrillation. J Am Geriatr Soc. 2012;60 (8):1434–41.
14. Garg Amit X, AdhikariNeill K J, McDonaldHeather, Rosas-ArellanoM 
Patricia, DevereauxP J, BeyeneJoseph, SamJustina, HaynesR Brian. Effects of 
computerized clinical decision support systems on practitioner performance and 
patient outcomes: a systematic review. JAMA. 2005;293 (10):1223–38.
15. Hunt D L, HaynesR B, HannaS E, SmithK. Effects of computer-based clinical 
decision support systems on physician performance and patient outcomes: a 
systematic review. JAMA. 1998;280 (15):1339–46.
16. Johnston M E, LangtonK B, HaynesR B, MathieuA. Effects of computer-based 
clinical decision support systems on clinician performance and patient outcome. A 
critical appraisal of research. Ann. Intern. Med. 1994;120 (2):135–42.
17. Berner E.S. Clinical decision support systems: theory and practice. Springer 
Science & Business Media. 2007;0:0–0.
18. Anchala Raghupathy, PintoMaria P, ShroufiAmir, ChowdhuryRajiv, 
SandersonJean, JohnsonLaura, BlancoPatricia, PrabhakaranDorairaj, FrancoOscar 
H. The role of Decision Support System (DSS) in prevention of cardiovascular 
disease: a systematic review and meta-analysis. PLoS ONE. 2012;7 (10):–.
19. Kaushal Rainu, ShojaniaKaveh G, BatesDavid W. Effects of computerized 
physician order entry and clinical decision support systems on medication safety: 
a systematic review. Arch. Intern. Med. 2003;163 (12):1409–16.
20. Wess Mark L, SchauerDaniel P, JohnstonJoseph A, MoomawCharles J, 
BrewerDavid E, CookE Francis, EckmanMark H. Application of a decision 
support tool for anticoagulation in patients with non-valvular atrial fibrillation. J 
Gen Intern Med. 2008;23 (4):411–7.
21. Simmons Brandon J, JennerKathleen M, DelateThomas, ClarkNathan P, 
KurzDeanna, WittDaniel M. Pilot study of a novel patient self-management 
program for warfarin therapy using venipuncture-acquired international 
normalized ratio monitoring. Pharmacotherapy. 2012;32 (12):1078–84.
22. Robson John, DostalIsabel, MathurRohini, SohanpalRatna, HullSally, 
AntoniouSotiris, MaccallumPeter, SchillingRichard, AyerbeLuis, BoomlaKambiz. 
Improving anticoagulation in atrial fibrillation: observational study in three 
primary care trusts. Br J Gen Pract. 2014;64 (622):e275–81.
www.jafib.com June-July 2017| Volume 10| Issue 1 
Featured ReviewJournal of Atrial FibrillationJ r l f tri l i rill ti7 Original Research
Int J Surg. 2010;8 (5):336–41.
40. Bajorek Beata, MaginParker, HilmerSarah, KrassInes. A cluster-randomized 
controlled trial of a computerized antithrombotic risk assessment tool to optimize 
stroke prevention in general practice: a study protocol. BMC Health Serv Res. 
2014;14 ():–.
41. Holt Tim A, FitzmauriceDavid A, MarshallTom, FayMatthew, QureshiNadeem, 
DaltonAndrew R H, HobbsF D Richard, LassersonDaniel S, KearleyKaren, 
HislopJenny, JinJing. Automated Risk Assessment for Stroke in Atrial Fibrillation 
(AURAS-AF)--an automated software system to promote anticoagulation and 
reduce stroke risk: study protocol for a cluster randomised controlled trial. Trials. 
2013;14 ():–.
